Lv1
40 积分 2025-07-23 加入
Role of the tumor microenvironment in CLL pathogenesis
46分钟前
待确认
Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study
27天前
已完结
Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
1个月前
已完结
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
1个月前
已完结
REPORT OF CONSENSUS PANEL 2 FROM THE 12TH INTERNATIONAL WORKSHOP ON THE MANAGEMENT OF BING-NEEL SYNDROME IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA
1个月前
已关闭
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
1个月前
已完结
Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy
1个月前
已完结
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
2个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
3个月前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
3个月前
已关闭
皖公网安备34019202002308
